Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Erratum: Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 31, 2026
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 21, 2024
Targeted cellular therapy for treatment of relapsed or refractory leukemia.
Journal: Best practice & research. Clinical haematology
Published: May 23, 2023
Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 03, 2022
Reverse translational studies inform dual-targeted CAR T-cell design.
Journal: Blood
Published: May 03, 2022
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: March 18, 2022
A Costimulatory CAR Improves TCR-based Cancer Immunotherapy.
Journal: Cancer immunology research
Published: April 22, 2021
Replacing CAR-T cell resistance with persistence by changing a single residue.
Journal: The Journal of clinical investigation
Published: May 05, 2020
Chimeric Antigen Receptors for T-Cell Malignancies.
Journal: Frontiers in oncology
Published: December 11, 2018
Showing 1-9 of 9
Last Updated: 09/26/2026